Denileukin diftitox

Denileukin diftitox
Clinical data
Trade names	Ontak, others
AHFS/Drugs.com	Monograph
MedlinePlus	a611024
License data	US DailyMed: Denileukin diftitox;
Routes of; administration	Intravenous
Drug class	Antineoplastic
ATC code	L01XX29 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Elimination half-life	70-80 min
Identifiers
	IUPAC name Diphtheria toxin-Interleukin-2 fusion protein;
CAS Number	173146-27-5 ;
IUPHAR/BPS	7044;
DrugBank	DB00004 ;
ChemSpider	none;
UNII	25E79B5CTM;
KEGG	D03682;
ChEMBL	ChEMBL1201550 ;
Chemical and physical data
Formula	C2560H4042N678O799S17
Molar mass	57647.46 g·mol−1
	(what is this?) (verify)

Denileukin diftitox, sold under the brand name Ontak among others, is an anti-cancer medication used for the treatment of adults with T-cell lymphoma. It is an IL2-receptor-directed cytotoxin. It is an engineered protein combining interleukin-2 and diphtheria toxin.^[3]

Medical uses

Denileukin diftitox is indicated for the treatment of adults with relapsed or refractory stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy.^[1]^[2]

Adverse effects

The prescription label contains a boxed warning that capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in people receiving denileukin diftitox.^[1]^[2]

Society and culture

Legal status

In 1999, denileukin diftitox was approved by the US Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma.^[1]^[4]

References

^ ^a ^b ^c ^d "Ontak (denileukin diftitox) Injection for intravenous infusion Initial U.S. Approval: 1999". DailyMed. Retrieved 9 August 2024.
^ ^a ^b ^c https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761312s000lbl.pdf
^ Turturro F (January 2007). "Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders". Expert Review of Anticancer Therapy. 7 (1): 11–7. doi:10.1586/14737140.7.1.11. PMID 17187516. S2CID 9028829.
^ Manoukian G, Hagemeister F (November 2009). "Denileukin diftitox: a novel immunotoxin". Expert Opinion on Biological Therapy. 9 (11): 1445–51. doi:10.1517/14712590903348135. PMID 19817678. S2CID 23956460.

External links

"Denileukin Diftitox (Code C1476)". NCI Thesaurus.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[Ontak_FDA_label-1] "Ontak (denileukin diftitox) Injection for intravenous infusion Initial U.S. Approval: 1999". DailyMed. Retrieved 9 August 2024.

[Lymphir_FDA_label-2] ttps://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761312s000lbl.pdf

[pmid17187516-3] Turturro F (January 2007). "Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders". Expert Review of Anticancer Therapy. 7 (1): 11–7. doi:10.1586/14737140.7.1.11. PMID 17187516. S2CID 9028829.

[pmid19817678-4] Manoukian G, Hagemeister F (November 2009). "Denileukin diftitox: a novel immunotoxin". Expert Opinion on Biological Therapy. 9 (11): 1445–51. doi:10.1517/14712590903348135. PMID 19817678. S2CID 23956460.

[3]

[1]

[2]

[4]